Recent breakthroughs in targeting commonly seen KRAS G12D mutations are exciting, with real potential to change the landscape of treatment for patients with metastatic pancreatic cancer; data from larger clinical trials are needed to confirm efficacy. This evidence concerns the gene KRAS and familial pancreatic carcinoma.